Source comparison
Comparison: BPC-157 vs Other Bone-Targeted Research Compounds
BPC-157 Angiogenesis, fibroblast migration, NOS stabilization Rodent fracture models show 20–30% faster radiographic union; no human trials; mechanism unclear for osteoblast activity 10 mcg/kg/day in animal models (500–700 mcg/day human equivalent) Subcutaneou
This comparison does not assign a generated winner or score.
- BPC-157
- Angiogenesis, fibroblast migration, NOS stabilization
- Rodent fracture models show 20–30% faster radiographic union; no human trials; mechanism unclear for osteoblast activity
- 10 mcg/kg/day in animal models (500–700 mcg/day human equivalent)
- Subcutaneous or intraperitoneal
- Promising for early-stage fracture healing in animals; human applicability unproven; may require administration within 48 hours of injury
- TB-500 (Thymosin Beta-4)
- Actin sequestration, cell migration, anti-inflammation
- Minimal bone-specific data; primarily studied for cardiac and muscle repair; one study showed improved osteoblast differentiation in vitro
- 2–5 mg twice weekly in soft tissue protocols
- Subcutaneous
- Weak evidence for bone healing; stronger track record in soft tissue contexts
- IGF-1 LR3
- Insulin-like growth factor receptor agonism, anabolic signaling
- Direct osteoblast proliferation; used in bone density research; systemic effects on glucose metabolism complicate research use
- 20–50 mcg/day in research models
- Mechanistically relevant to bone formation but systemic side effects limit targeted application
- BMP-2 (Bone Morphogenetic Protein-2)
- Direct osteoblast differentiation and bone matrix formation
- FDA-approved for spinal fusion; extensive clinical evidence; risk of ectopic bone formation
- Clinical doses 1.5 mg/mL on collagen sponge
- Surgical implantation at fracture site
- Gold standard for bone regeneration research; requires localized delivery; not suitable for systemic administration